Q4 2024 PetVivo Holdings Inc Earnings Call Transcript
Key Points
- Revenue increased by 6% to $969,000, driven by sales of the lead veterinary medical device Spryng.
- Gross profit improved by 6% to $740,000 with gross margins increasing by 40 basis points to 76.3%.
- Distribution of Spryng reached over 600 veterinary clinics across 49 states, with more than 4,500 syringes distributed nationwide.
- Positive results from two key clinical animal studies, enhancing the credibility and marketability of Spryng.
- Successful partnership with Covetrus North America, contributing $106,000 in sales, representing 11% of total revenues for the year.
- Operating expenses increased by 20% to $11.4 million, driven by higher G&A costs and R&D expenses.
- Net loss widened to $11 million or $0.17 per share, compared to a net loss of $8.7 million or $0.85 per share in the previous year.
- Sales to veterinary clinics decreased by 16% to $237,000 due to the transition from equine to companion animals.
- Cash and cash equivalents were low at $87,000 as of March 31, 2024, indicating potential liquidity issues.
- The company had to raise $1.8 million through a private equity offering to bolster its financial position.
Welcome, everyone. To let everyone get into the call, we'll wait at least one minute before we start.
Good afternoon, and thank you for joining us today to discuss PetVivo's results for its fiscal year ended March 31, 2024. Hosting the call today is Chief Executive Officer of PetVivo, John Lai; the company's Chief Financial Officer, Garry Lowenthal; and me, John Dolan, the company's Chief Business Development Officer and General Counsel.
Following our remarks and at the end of this call, we'll open the call to your questions. But before we conclude today's call, I'll provide some important cautions regarding forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded, and it will be made available for telecom replay per the instructions in today's press release, which is available in the Investor Relations section of the company's website.
Now I'd like to turn the call over to the PetVivo CFO,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
